Get the Stockscreener App
13.81
7.07%
-1.05
After Hours:
13.81
Contineum Therapeutics Inc stock is traded at $13.81, with a volume of 397.79K.
It is down -7.07% in the last 24 hours and down -4.63% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$14.86
Open:
$14.61
24h Volume:
397.79K
Relative Volume:
1.64
Market Cap:
$504.47M
Revenue:
$50.00M
Net Income/Loss:
$-59.39M
P/E Ratio:
-6.122
EPS:
-2.2558
Net Cash Flow:
$-53.08M
1W Performance:
-12.48%
1M Performance:
-4.63%
6M Performance:
+20.09%
1Y Performance:
+126.39%
1-Day Range:
$13.20
$14.68
1-Week Range:
$13.20
$15.76
52-Week Range:
$3.35
$16.33
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
13.81 | 542.83M | 50.00M | -59.39M | -53.08M | -2.2558 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
USD News Center - University of San Diego
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
Contineum Therapeutics to Present at September Investor Conferences - Business Wire
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares By Investing.com - Investing.com UK
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares - Investing.com
Contineum Therapeutics (CTNM) CMO sells $54,220 in stock - Investing.com
Contineum Therapeutics (CTNM) CSO sells shares under 10b5-1 plan - Stock Titan
Contineum Therapeutics (CTNM) CMO sells 3,611 shares via 10b5-1 - Stock Titan
Beat the Market with Zacks: Spotlight on Contineum Therapeutics, Suzano, and PepsiCo - Bitget
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus - Yahoo Finance
Earnings Beat: Is Contineum Therapeutics Inc gaining market shareJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Contineum Therapeutics CSO Lorrain S. Daniel sells $130k in CTNM stock By Investing.com - Investing.com South Africa
Contineum Therapeutics CSO Lorrain S. Daniel sells $130k in CTNM stock - Investing.com
Contineum Therapeutics (CTNM) CEO sells 7,100 shares, exercises options - Stock Titan
Contineum Therapeutics (CTNM) CSO exercises options and sells 8,124 shares - Stock Titan
Contineum Therapeutics (CTNM) Projected to Post Earnings on Thursday - MarketBeat
CTNM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Contineum Therapeutics Inc gaining market shareEarnings Summary Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of “Moderate Buy” by Analysts - Defense World
CTNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Balyasny Asset Management L.P. Increases Stake in Contineum Ther - GuruFocus
Balyasny Asset Management L.P. Increases Stake in Contineum Therapeutics Inc. - GuruFocus
What’s the MACD signal for Contineum Therapeutics Inc.July 2025 Snapshot & Daily Volume Surge Signals - mfd.ru
A | Can IRDM navigate macro headwindsJuly 2025 Movers & Consistent Return Strategy Ideas - mfd.ru
Contineum (NASDAQ: CTNM) CSO trades shares under 10b5-1 plan - Stock Titan
Will Contineum Therapeutics Inc. stock continue dividend increasesJuly 2025 Opening Moves & Verified Momentum Stock Ideas - mfd.ru
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
RA Capital discloses 7.2% Contineum Therapeutics (CTNM) ownership stake - Stock Titan
Balyasny discloses 7.6% Contineum (CTNM) stake via ADMF fund - Stock Titan
Published on: 2026-02-15 23:21:35 - mfd.ru
Can Contineum Therapeutics Inc. stock outperform in a bear marketTrade Exit Summary & Entry Point Strategy Guides - mfd.ru
Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Contineum (CTNM) CEO exercises options and sells 400 shares - Stock Titan
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - MSN
Why is Contineum Therapeutics Inc. stock going down2025 Earnings Impact & Daily Profit Focused Stock Screening - mfd.ru
Insider Daniel Lorrain plans 16,050-share sale at CTNM (NASDAQ: CTNM) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Boston Scientific (BSX) - The Globe and Mail
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - MSN
Entry Recap: How sensitive is Contineum Therapeutics Inc to inflationQuarterly Earnings Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Franklin Resources Inc. Expands Holdings in Contineum Therapeuti - GuruFocus
Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Trend Review: Is SFBS a top pick in the sectorOptions Play & AI Driven Stock Price Forecasts - baoquankhu1.vn
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Contineum Therapeutics reports inducement grant under Nasdaq Listing Rule - marketscreener.com
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule - TradingView
Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions - Yahoo Finance
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan - The Globe and Mail
Big Money Moves: Will Contineum Therapeutics Inc stock recover after earningsMarket Performance Recap & High Conviction Trade Alerts - baoquankhu1.vn
Aug EndMonth: Is Contineum Therapeutics Inc currently under institutional pressureWeekly Trend Summary & Long-Term Capital Growth Strategies - baoquankhu1.vn
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):